Searched for
BRITISH DRUGMAKER
Global Markets: European shares edge higher with banks in the lead; the Middle East in focusEuropean markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after ...- GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studiesGSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achievi...
- Global Markets | European shares subdued as US-Iran talks stall; corporate earnings on tapEuropean shares were muted on Tuesday as investors braced for a week packed with central bank meetings and corporate earnings, while weighi...
- UK to offer to pay more for some drugs to appease Trump: ReportThe British government will offer to pay more for medicines bought by the NHS, aiming to defuse U.S. President Donald Trump's complaints ab...
- European shares flat as tech losses counter healthcare boostEuropean shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo Nordisk's strong earnings...
- Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunnerPfizer is selling around 700 million ordinary shares in Haleon, reducing its stake from 15% to about 7.3%. This sale follows its earlier re...
- GSK to buy US biotech firm IDRx for up to $1.15 billionBritish drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion paymen...
- GSK raises $1.5 billion from sale of remaining Haleon stakeBritish drugmaker GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Hale...
- GSK CEO Emma Walmsley's total pay rises 51% to nearly 13 mln pounds in 2023GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, driven by a significant increase in perfo...
- GSK's RSV vaccine succeeds in late-stage trial for older adultsThe RSV vaccine is a key component of the British drugmaker's plans to boost its drug development success rate as it prepares to spin off i...
- Pfizer to exit GSK's consumer health arm Haleon after spin-offBefore the spinoff, the holding company for the consumer health business will pay dividends to GSK and Pfizer. That will translate to GSK r...
- AstraZeneca, Oxford expect 'next generation' COVID-19 vaccine to tackle variants by autumn - executiveAsked when AstraZeneca could produce a next generation vaccine to tackle new variants, AstraZeneca research chief Mene Pangalos said "as ra...
- Russia, AstraZeneca to test combination of COVID-19 shotsDevelopers of the Russian coronavirus vaccine Sputnik V on Monday announced signing an agreement with AstraZeneca to test a combination of ...
- Post trial results, AstraZeneca CEO says smaller first dose in COVID-19 vaccine is 'big plus'The British drugmaker said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects.
- AstraZeneca to make billion Covid vaccine doses if tests succeedThe British drugmaker said it had signed the first agreements to supply at least 400 million doses of the vaccine, which it is developing w...
- British PM Cameron says government talking to Pfizer, AstraZenecaDavid Cameron said the government would continue to talk to both Pfizer and AstraZeneca after the British drugmaker rejected an offer.
- Pfizer has not discussed AstraZeneca bid with regulators: European Union's AlmuniaPfizer is seeking to acquire Britain's second-biggest drugmaker and may have to sweeten its offer after AstraZeneca rejected the bid.
- UK's Cameron wants 'best possible' Pfizer guarantees on AstraZenecaCameron said on Wednesday he was seeking the best possible guarantees from U.S. drugmaker Pfizer over its potential takeover of AstraZeneca.
- Chinese police to brief media on GlaxoSmithKline amid probeThe company has said previously that some of its senior Chinese executives appear to have broken law and it has zero tolerance for bribery.
- Pfizer says keen to engage with AstraZeneca boardAstraZeneca has rejected a $106 billion bid from Pfizer but the US group is widely expected to return with a higher offer later this week.
Load More
